(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 7. FGFR2b and the FGF10-FGFR2b complex colocalize with endogenous SMG
perlecan HS, and the binding is decreased by heparanase treatment. A
whole-mount ligand and carbohydrate engagement (LACE) assay using E13 SMGs
shows that FGFR2b (A) and the FGF10-FGFR2b complex (B)
colocalize with perlecan in the basement membrane. Increased binding was
detected with the complex compared to the receptor alone. There was decreased
binding of both FGFR2b and the FGF10-FGFR2b complex after heparanase or
heparitinase treatment. In addition, the FGF10-FGFR2b complex also colocalizes
with syndecan 1 in the epithelium (C), but also binds other epithelial
HSPGs, and the staining was not decreased by pretreatment with either
heparanase or heparitinase (data not shown). Images are single confocal
sections. Scale bar: 20 µm in A and B; 10 µm in C.